SCHEMBL9890748

SCHEMBL9890748

CNC(=O)Cc1ccccc1-c1ccc(C(F)(F)F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.46
CYP11B2 P19099 3/20 0.46
RORC P51449 2/20 0.44
TRPA1 O75762 1/20 0.44
TRPV4 Q9HBA0 1/20 0.44
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.42
RORA P35398 1/20 0.41
CSNK1D P48730 2/20 0.41
APP P05067 1/20 0.41
NTRK1 P04629 1/20 0.40
CETP P11597 1/20 0.40
HSD11B1 P28845 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
ANO1 Q5XXA6 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395314 0.82 RAB9A (0.49) KDM4E
SCHEMBL2395131 0.81 KCNJ5 (0.49) CYP11B1CYP11B2RORCKCNJ5KCNJ3
SCHEMBL2393347 0.81 RORC (0.48) RORCTRPA1
SCHEMBL9892682 0.80 P2RX7 (0.42) RORCKCNJ5KCNJ3NTRK1
SCHEMBL9892662 0.79 PTGDR2 (0.50) KCNJ5KCNJ3PTGDR2
SCHEMBL9892679 0.79 PTGDR2 (0.47) PTGDR2
SCHEMBL9890753 0.79 RXRA (0.46) TRPA1KCNJ5KCNJ3RORAGPBAR1
SCHEMBL2392432 0.78 MEN1 (0.44) RORCKCNJ5KCNJ3ANO1KDM4E
SCHEMBL9892661 0.77 P2RX7 (0.42) KCNJ5KCNJ3CSNK1DNTRK1ANO1
SCHEMBL9890749 0.76 P2RX7 (0.46) TRPA1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP11B1 307/4885CYP11B2 206/4885RORC 1513/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP11B1 307/4885CYP11B2 206/4885RORC 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.